Cardiovascular Calcification in Chronic Kidney Disease—Therapeutic Opportunities
Patients with chronic kidney disease (CKD) are highly susceptible to cardiovascular (CV) complications, thus suffering from clinical manifestations such as heart failure and stroke. CV calcification greatly contributes to the increased CV risk in CKD patients. However, no clinically viable therapies...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-03-01
|
| Series: | Toxins |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6651/12/3/181 |
| _version_ | 1811184610800828416 |
|---|---|
| author | Anika Himmelsbach Carina Ciliox Claudia Goettsch |
| author_facet | Anika Himmelsbach Carina Ciliox Claudia Goettsch |
| author_sort | Anika Himmelsbach |
| collection | DOAJ |
| description | Patients with chronic kidney disease (CKD) are highly susceptible to cardiovascular (CV) complications, thus suffering from clinical manifestations such as heart failure and stroke. CV calcification greatly contributes to the increased CV risk in CKD patients. However, no clinically viable therapies towards treatment and prevention of CV calcification or early biomarkers have been approved to date, which is largely attributed to the asymptomatic progression of calcification and the dearth of high-resolution imaging techniques to detect early calcification prior to the ‘point of no return’. Clearly, new intervention and management strategies are essential to reduce CV risk factors in CKD patients. In experimental rodent models, novel promising therapeutic interventions demonstrate decreased CKD-induced calcification and prevent CV complications. Potential diagnostic markers such as the serum T50 assay, which demonstrates an association of serum calcification propensity with all-cause mortality and CV death in CKD patients, have been developed. This review provides an overview of the latest observations and evaluates the potential of these new interventions in relation to CV calcification in CKD patients. To this end, potential therapeutics have been analyzed, and their properties compared via experimental rodent models, human clinical trials, and meta-analyses. |
| first_indexed | 2024-04-11T13:15:15Z |
| format | Article |
| id | doaj.art-d428f2199a7343eea6e403685e4d4491 |
| institution | Directory Open Access Journal |
| issn | 2072-6651 |
| language | English |
| last_indexed | 2024-04-11T13:15:15Z |
| publishDate | 2020-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Toxins |
| spelling | doaj.art-d428f2199a7343eea6e403685e4d44912022-12-22T04:22:25ZengMDPI AGToxins2072-66512020-03-0112318110.3390/toxins12030181toxins12030181Cardiovascular Calcification in Chronic Kidney Disease—Therapeutic OpportunitiesAnika Himmelsbach0Carina Ciliox1Claudia Goettsch2Department of Internal Medicine I, Cardiology, Medical Faculty, RWTH, Aachen University, 52074 Aachen, GermanyDepartment of Internal Medicine I, Cardiology, Medical Faculty, RWTH, Aachen University, 52074 Aachen, GermanyDepartment of Internal Medicine I, Cardiology, Medical Faculty, RWTH, Aachen University, 52074 Aachen, GermanyPatients with chronic kidney disease (CKD) are highly susceptible to cardiovascular (CV) complications, thus suffering from clinical manifestations such as heart failure and stroke. CV calcification greatly contributes to the increased CV risk in CKD patients. However, no clinically viable therapies towards treatment and prevention of CV calcification or early biomarkers have been approved to date, which is largely attributed to the asymptomatic progression of calcification and the dearth of high-resolution imaging techniques to detect early calcification prior to the ‘point of no return’. Clearly, new intervention and management strategies are essential to reduce CV risk factors in CKD patients. In experimental rodent models, novel promising therapeutic interventions demonstrate decreased CKD-induced calcification and prevent CV complications. Potential diagnostic markers such as the serum T50 assay, which demonstrates an association of serum calcification propensity with all-cause mortality and CV death in CKD patients, have been developed. This review provides an overview of the latest observations and evaluates the potential of these new interventions in relation to CV calcification in CKD patients. To this end, potential therapeutics have been analyzed, and their properties compared via experimental rodent models, human clinical trials, and meta-analyses.https://www.mdpi.com/2072-6651/12/3/181chronic kidney diseasecardiovascular diseasevascular calcificationexperimental rodent models |
| spellingShingle | Anika Himmelsbach Carina Ciliox Claudia Goettsch Cardiovascular Calcification in Chronic Kidney Disease—Therapeutic Opportunities Toxins chronic kidney disease cardiovascular disease vascular calcification experimental rodent models |
| title | Cardiovascular Calcification in Chronic Kidney Disease—Therapeutic Opportunities |
| title_full | Cardiovascular Calcification in Chronic Kidney Disease—Therapeutic Opportunities |
| title_fullStr | Cardiovascular Calcification in Chronic Kidney Disease—Therapeutic Opportunities |
| title_full_unstemmed | Cardiovascular Calcification in Chronic Kidney Disease—Therapeutic Opportunities |
| title_short | Cardiovascular Calcification in Chronic Kidney Disease—Therapeutic Opportunities |
| title_sort | cardiovascular calcification in chronic kidney disease therapeutic opportunities |
| topic | chronic kidney disease cardiovascular disease vascular calcification experimental rodent models |
| url | https://www.mdpi.com/2072-6651/12/3/181 |
| work_keys_str_mv | AT anikahimmelsbach cardiovascularcalcificationinchronickidneydiseasetherapeuticopportunities AT carinaciliox cardiovascularcalcificationinchronickidneydiseasetherapeuticopportunities AT claudiagoettsch cardiovascularcalcificationinchronickidneydiseasetherapeuticopportunities |